Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib

Dig Liver Dis. 2019 Oct;51(10):1488-1490. doi: 10.1016/j.dld.2019.07.005. Epub 2019 Aug 7.

Authors

Zeyu Zhang¹, Yufan Zhou¹, Kuan Hu¹, Zhecheng Li¹, Zhiming Wang¹, Yun Huang²

Affiliations

¹ Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: huangyun-1002@163.com.

PMID: 31401020
DOI: 10.1016/j.dld.2019.07.005

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Hepatocellular / diagnostic imaging
Carcinoma, Hepatocellular / drug therapy*
Humans
Liver Neoplasms / diagnostic imaging
Liver Neoplasms / drug therapy*
Magnetic Resonance Imaging
Male
Middle Aged
Pyridines / therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Pyridines
apatinib
camrelizumab